Roivant Sciences Ltd. (ROIV) Jefferies London Healthcare Convention 2025 November 18, 2025 12:00 PM EST
Firm Contributors
Matthew Gline – CEO & Director
Convention Name Contributors
Yuchen Ding – Jefferies LLC, Analysis Division
Presentation
Yuchen Ding
Jefferies LLC, Analysis Division
Good afternoon. Welcome to the Jefferies Healthcare Convention in London. My identify is Dennis Ding, biotech analyst right here at Jefferies. I’ve the fantastic pleasure of getting the CEO of Roivant right here with us. Matt, welcome.
Matthew Gline
CEO & Director
Thanks. Thanks for having me. I really feel like I’m all the pieces that’s standing between these individuals and a drink.
Query-and-Reply Session
Yuchen Ding
Jefferies LLC, Analysis Division
That is true. I assume, look, 2025 has been fairly a transformational 12 months for the corporate. Plenty of items that you simply guys have arrange over the past a number of years have performed out this 12 months positively for the corporate. However possibly simply spotlight a number of the progress and a number of the information that you simply guys have reported this 12 months which have generated a lot pleasure.
Matthew Gline
CEO & Director
Sure. Thanks. Sure. Look, it is — it is all the time enjoyable. Look, the nerve-racking factor about biotech is you plant seeds after which it takes a very long time to see what is going on to come back out of them, and it is all the time enjoyable to form of see it actualize. So Roivant is a remodeled firm relative to earlier this 12 months. So we’re — for individuals who do not know us very properly, we’re a few $14.5 billion market cap, now public biopharma firm, principally centered on creating late-stage medication that we expect ought to matter for underserved affected person populations. That is in all probability what half the businesses on the stage have stated as we speak.
And this 12 months, specifically, our portfolio has moved ahead in a extremely significant approach, in all probability throughout
